A5102945783- Venous Thromboembolism Diagnosis and Management
- Cerebral Venous Sinus Thrombosis
- Atrial Fibrillation Management and Outcomes
- Blood Coagulation and Thrombosis Mechanisms
- Acute Ischemic Stroke Management
- Intracerebral and Subarachnoid Hemorrhage Research
- Neurosurgical Procedures and Complications
- Lipoproteins and Cardiovascular Health
- Cardiac Arrhythmias and Treatments
- Sepsis Diagnosis and Treatment
- Antiplatelet Therapy and Cardiovascular Diseases
- Vascular Malformations Diagnosis and Treatment
- Platelet Disorders and Treatments
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cerebrovascular and Carotid Artery Diseases
- Complement system in diseases
- COVID-19 Clinical Research Studies
- Systemic Lupus Erythematosus Research
- SARS-CoV-2 and COVID-19 Research
- Liver Disease and Transplantation
- Assisted Reproductive Technology and Twin Pregnancy
- Long-Term Effects of COVID-19
- Blood groups and transfusion
- Reproductive Health and Contraception
- Diabetes, Cardiovascular Risks, and Lipoproteins
University of Insubria
2014-2025
Aziende Socio Sanitarie Territoriale dei Sette Laghi
2023
Fondazione FADOI
2023
ATS Sardegna (Italy)
2020
Ospedale di Circolo e Fondazione Macchi
2007-2014
Hy-Line (United States)
2009
University of Padua
2007
McMaster University
2005-2006
Background and purpose Current guidelines on cerebral venous thrombosis ( CVT ) diagnosis management were issued by the European Federation of Neurological Societies in 2010. We aimed to update previous using a clearer evidence‐based methodology. Method followed Grading Recommendations, Assessment, Development Evaluation system, formulating relevant diagnostic treatment questions, performing systematic reviews writing recommendations based quality available scientific evidence. Results...
Patients with cerebral venous thrombosis (CVT) are at risk of recurrent thrombotic events (VTEs). Non-vitamin K oral anticoagulants have not been evaluated in randomized controlled trials CVT.To compare the efficacy and safety dabigatran etexilate those dose-adjusted warfarin preventing VTEs patients who experienced a CVT.RE-SPECT CVT is an exploratory, prospective, (1:1), parallel-group, open-label, multicenter clinical trial blinded end-point adjudication (PROBE design). It was performed...
The current proposal for cerebral venous thrombosis guideline followed the Grading of Recommendations, Assessment, Development, and Evaluation system, formulating relevant diagnostic treatment questions, performing systematic reviews all available evidence writing recommendations deciding on their strength an explicit transparent manner, based quality scientific evidence. addresses both therapeutic topics. We suggest using magnetic resonance or computed tomography angiography confirming...
Patients who not only survive a warfarin-associated gastrointestinal tract bleeding (GIB) event but also have an ongoing risk for thromboembolism present 2 clinical dilemmas: whether and when to resume anticoagulation. The objective of this study was determine the incidence thrombosis, recurrent GIB, death, as well time resumption anticoagulant therapy, during 90 days following GIB event.In retrospective, cohort using administrative databases, patients experiencing warfarin therapy were...
The effect of antibiotic coadministration on the international normalized ratio (INR) in a relatively stable, real-world warfarin population has not been adequately described. Case reports and studies healthy volunteers do account for potential contribution acute illness to INR variability.To compare risk excessive anticoagulation among patients with stable therapy purchasing an (antibiotic group) refill (stable controls) upper respiratory tract infection but receiving (sick controls).A...
Background The effect of different anticoagulants on recanalization after cerebral venous thrombosis has not been studied in a randomized controlled trial. Methods RE-SPECT CVT (ClinicalTrials.gov number: NCT02913326) was Phase III, prospective, randomized, parallel-group, open-label, multicenter, exploratory trial with blinded endpoint adjudication. Acute patients were allocated to dabigatran 150 mg twice daily, or dose-adjusted warfarin, for 24 weeks, 5–15 days’ treatment unfractionated...
This analysis examined the frequency of dural arteriovenous fistulae (dAVF) after cerebral venous thrombosis (CVT) in patients included a randomized controlled trial comparing dabigatran etexilate with dose-adjusted warfarin (RE-SPECT CVT [A Clinical Trial Comparing Efficacy and Safety Dabigatran Etexilate With Warfarin Patients Cerebral Venous Dural Sinus Thrombosis]), who had systematic follow-up magnetic resonance (MR) imaging.RE-SPECT was Phase 3, prospective, randomized, parallel-group,...
Introduction Current guidelines recommend that patients with cerebral venous thrombosis (CVT) should be treated vitamin K antagonists (VKAs) for 3–12 months. Direct oral anticoagulants (DOACs), however, are increasingly used in clinical practice. An exploratory randomized controlled trial including 120 CVT suggested the efficacy and safety profile of dabigatran (a DOAC) is similar to VKAs treatment CVT, but large-scale prospective studies from a real-world setting lacking. Methods DOAC-CVT...